Jefferies Names Possible Hedge Fund Short Targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Biogen (BIIB) Reports FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
February 1, 2021 7:33 AM ESTBiogen Inc. (NASDAQ: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This... More
RBC Capital Reiterates Sector Perform Rating on Pfizer (PFE)
February 1, 2021 6:49 AM ESTRBC Capital analyst Randall Stanicky reiterated a Sector Perform rating and $42.00 price target on Pfizer (NYSE: PFE) ahead of the company's 4Q earnings release. PFE is set to report 4Q results this Tuesday. Stanicky thinks the 4Q set up is relatively favorable on the back... More
Stifel Upgrades Biogen (BIIB) to Buy
January 29, 2021 8:48 AM ESTStifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $358.00 (from $258.00).
The analyst comments "Our initial reaction after the Aducanumab AdComm was that the path to FDA approval seems challenging. Since, Biogen management's... More
